NCT05345691View on ClinicalTrials.gov

Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

479

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

June 12, 2024

Study Completion Date

June 12, 2024

Conditions
Postmenopausal Women With Osteoporosis
Interventions
BIOLOGICAL

Bmab 1000

60 mg administered as a single SC (subcutaneous) injection once every 6 months.

BIOLOGICAL

Prolia®

60 mg administered as a single SC injection once every 6 months

Trial Locations (1)

CB21 6GQ

PPD Global Ltd, Granta Park, Great Abington,, Cambridge

Sponsors
All Listed Sponsors
lead

Biocon Biologics UK Ltd

INDUSTRY

NCT05345691 - Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis | Biotech Hunter | Biotech Hunter